CSF1R and Hodgkins lymphoma: To date clinical trials for CSF-1/CSF-1R blockade have been completed in non-pancreatic neuroendocrine tumors (89), Hodgkin lymphoma (90), ovarian cancer (NCT03166891, NCT03901118), non-Hodgkin lymphoma (NCT03974243) and hepatocellular carcinoma (NCT03245190).